click below
click below
Normal Size Small Size show me how
pharmacology 5
| Term | Definition |
|---|---|
| Anxiolytic | Drug used to treat anxiety enhance binding of γ-aminobutyric acid (GABA) GABAA receptor binding causes chloride ion (Cl−) channels to open The influx of chloride ions decreases neuronal excitability. |
| generalized anxiety disorder.: | Condition that is associated with excessive worrying and tension that is experienced daily for more than 6 months. |
| Obsessive-compulsive disorder | A condition associated with an inability to control or stop repeated unwanted thoughts or behaviors |
| Panic disorder | Condition associated with repeated sudden onset of feelings of terror ⬤ Occurs twice as frequently in women as in men. ⬤ It may be accompanied by major depression. ⬤ may be triggered by a phobia. |
| Phobia | Irrational fear of things or situations that produce symptoms of intense anxiety |
| Posttraumatic stress disorder | Stress disorder that develops in persons who have participated in, witnessed, or been a victim of a terrifying event. |
| Social anxiety disorder | A chronic mental health condition in which social interactions cause irrational anxiety affects 15 million adults or 6.8% of the US population ⬤ Women are twice as likely to be affected as men. |
| Population most likley to develop generalized anxiety disorder.: | 1.1% of Canadians between the ages of 15 and 64 Women are twice as likely as men to be diagnosed . |
| Drugs that affect the neurotransmitters administered for the treatment of anxiety. | ⮚ γ-aminobutyric acid (GABA) ⮚ Serotonin (5-HT) ⮚ Norepinephrine (NE) |
| Benzodiazepines | used in the treatment of short-term anxiety High degree of lipid solubility ⮚ Accounts for their rapid and complete absorption ⮚ Enables the drugs to readily cross the blood–brain barrier |
| Azapirones | Buspirone do not produce tolerance or dependence. ⬤ Maximum therapeutic effects are achieved 1 to 3 weeks ⬤ Food increases the drug’s bioavailability ⬤ partial agonists at the 5-HT1A receptors. |
| Benzodiazepines: Adverse Reactions | ⬤ Sedation ⬤ Ataxia (the loss of full control of bodily movements.) ⬤ Confusion ⬤ Reduced motor performance ⬤ Reduced cognitive functions and memory (amnesia) ⬤ Tolerance and dependence |
| Buspirone: Adverse Reactions | ⬤ Dizziness ⬤ Restlessness ⬤ Headache ⬤ Nausea ⬤ Diarrhea ⬤ Insomnia |
| Hydroxyzine | antihistamine approved for the treatment of anxiety. histamine-1 receptor antagonist. contraindicated in men with prostate disease and in lactating women |
| Hydroxyzine: Adverse Reactions | ⬤ Sedation ( increased when taken with other CNS depressants or alcohol) ⬤ Dizziness ⬤ Headache ⬤ Dry mucous membranes ⬤ Urinary retention |
| Antidepressants Used in the Treatment of OCD | Clomipramine, Fluoxetine and sertralin |
| Sertraline | Antidepressants Used in the Treatment of OCD, panic disorder, social phobia, and posttraumatic stress disorder. |
| Mechanism of Action of ssris | inhibit 5-HT reuptake into the presynaptic neuron, increasing 5-HT availability at postsynaptic receptor sites. |
| MOA tricyclic antidepressants (TCAS) | inhibit the reuptake of 5-HT and noradrenaline |
| 5-HT | serotonin |
| MOA MAOI | binding increases synaptic availability of 5-HT, noradrenaline, and dopamine. |
| Beta-Adrenergic Antagonists | BETA-BLOCKERS EX propranolol are administered to reduce palpitations due to anxiety not approved by the FDA for the treatment of anxiety |
| Benzodiazepine Warning Labels | ⬤ May cause drowsiness; may impair ability to drive ⬤ Avoid alcohol ⬤ May be habit forming ⬤ Do not crush, break, or chew (extended release) |
| Buspirone Warning Labels | ⬤ May cause dizziness or drowsiness ⬤ May impair ability to drive ⬤ Take with food ⬤ Should be used with caution in patients with liver or kidney diseasE |
| Hydroxyzine Warning Labels | ⬤ May cause drowsiness; alcohol may intensify this effect ⬤ May impair ability to drive |